Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (30)

1

Targeting the DNA damage response for cancer therapy

enthalten in: Biochemical Society transactions | 2023

von Curtin, N.

2

Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

enthalten in: British journal of pharmacology | 2020

von Curtin, N. | Bányai, K. | Thaventhiran, J. | +3

3

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

enthalten in: Biochemical pharmacology | 2019

von Mukhopadhyay, A. | Drew, Y. | Matheson, E. | +4

4

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

5

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

enthalten in: British journal of cancer | 2016

von Drew, Y. | Ledermann, J. | Hall, G. | +14

CommentIn: Br J Cancer. 2016 Mar 29;114(7):713-5. - PMID 27022824

6

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

7

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

8

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

9

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

enthalten in: Haematologica | 2013

von Gaymes, T. | Mohamedali, A. | Patterson, M. | +8

10

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10